GLPG-0259

Names

[ Name ]:
GLPG-0259

Biological Activity

[Description]:

GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[Target]

MAPK-activated protein kinase 5 (MK5)[1]

[In Vitro]

GLPG0259 能够减少炎症和骨降解介质的释放，但不影响 c-jun NH(2)-末端蛋白激酶 (JNK)、ERK 和 p38 MAP 激酶的磷酸化[1]。 GLPG0259 (1-5 μM; 48 h) 导致前列腺癌 (PCa) 细胞株 LNCaP 和 PC3 中，肌动蛋白丝状减少和重塑[2]。

[In Vivo]

GLPG0259 (2 mg/kg, 10 mg/kg;腹腔注射; 每周 2 次, 共 7 周) 在携带有前列腺癌细胞系 P3 细胞 (i.v.) 的 SCID 米色小鼠中，抑制肿瘤细胞在肺转移[2].

[References]

[1]. Westhovens R, et al. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Ann Rheum Dis. 2013 May;72(5):741-4.

[2]. Khalil MI, et al. The TLK1-MK5 Axis Regulates Motility, Invasion, and Metastasis of Prostate Cancer Cells. Cancers (Basel). 2022 Nov 22;14(23):5728.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₄H₂₈N₈O₂

[ Molecular Weight ]:
460.53200

[ Exact Mass ]:
460.23400

[ PSA ]:
117.82000

[ LogP ]:
3.92350

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.